The AIIMS ( All India Institute of Medical Sciences) situated in Delhi is about to start phase I/II of Covaxin human clinical trials.
Among 12 different sites where human trials will begin, AIIMS is the one of them.
After India’s top drug regulator gave green signal for Covaxin trial, the DCGI ( Drugs controller general of India) have started clinical trials at AIIMS.
With collaboration of Hyderabad based Bharat Biotech and ICMR ( Indian council for Medical research ) and also with National Institute of virology Covaxin has been developed.
In phase I,the vaccine would be tested on 375 volunteers and maximum of hundred them would be basically from AIIMS Delhi.
Volunteers should be healthy with no comorbid conditions and without a history of covid-19.
Their age should be between 18 to 55 years.
To participate in human trials of COVAXIN, volunteers can send an email to Ctaiims.covid19@gmail.com or an SMS to or call on 7428847499.
Two covid-19 vaccine COVAXIN by Bharat Biotech international limited with ICMR and NIV and ZyCov-D vaccine by Zydus cadila had recently got green signal for human trials from DCGI ( Drug controller general of India ) . Both are up for phase II and phase III trials.
Bharat biotech in collaboration with ICMR ( Indian council of medical research ) developed Covid-19 vaccine called COVAXIN . Over seven vaccines are being researched in India and only COVAXIN and Zydus cadilla got the approval to start human trials . ICMR is looking to launch COVAXIN by August 15 on India’s independence day . After getting green signal from all the concerned authorities .
ALSO READ –
